Update on development of biosimilar versions of adalimumab with particular focus on excipients and injection site reactions

David Erskine, Director, London Medicines Information Services, Specialist Pharmacy ServicePublished
Topics: AdalimumabExcipientsTrusts

An overview of the five versions of adalimumab currently available in the UK. These article focuses on the differences in excipients and in particular the evidence of the relationship between  the presence of citrate in the formulation and the incidence of injection site reactions.  The document also provides a comparison of the five brands in terms of administration devices available.